Guido Reifenberger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3075137/publications.pdf

Version: 2024-02-01

169 papers	49,227 citations	6613 79 h-index	6131 159 g-index
172 all docs	172 docs citations	172 times ranked	34596 citing authors

#	Article	IF	Citations
1	Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic Taoism. Redox Biology, 2022, 49, 102221.	9.0	6
2	Development and external validation of a clinical prediction model for survival in patients with IDH wild-type glioblastoma. Journal of Neurosurgery, 2022, 137, 914-923.	1.6	7
3	Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation. Cell Death Discovery, 2022, 8, 91.	4.7	6
4	Droplet digital PCR-based analyses for robust, rapid, and sensitive molecular diagnostics of gliomas. Acta Neuropathologica Communications, 2022, 10, 42.	5.2	15
5	EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma. Cell Death Discovery, 2022, 8, 157.	4.7	3
6	The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. Nature Communications, 2022, 13, .	12.8	16
7	Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide. Journal of Cancer Research and Clinical Oncology, 2021, 147, 253-262.	2.5	8
8	The molecular evolution of glioblastoma treated by gross total resection alone. Neuro-Oncology, 2021, 23, 334-336.	1.2	2
9	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	27.6	826
10	<scp>MGMT</scp> promoter methylation analysis for allocating combined <scp>CCNU</scp>/<scp>TMZ</scp> chemotherapy: Lessons learned from the <scp>CeTeG</scp>/<scp>NOA</scp>â€09 trial. International Journal of Cancer, 2021, 148, 1695-1707.	5.1	11
11	Chemotherapy for adult patients with spinal cord gliomas. Neuro-Oncology Practice, 2021, 8, 475-484.	1.6	1
12	Telomerase reverse transcriptase promoter mutationâ€“ and O6-methylguanine DNA methyltransferase promoter methylationâ€“mediated sensitivity to temozolomide in isocitrate dehydrogenaseâ€–wild-type glioblastoma: is there a link?. European Journal of Cancer, 2021, 147, 84-94.	2.8	10
13	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€“Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	9.4	39
14	A common classification framework for histone sequence alterations in tumours: an expert consensus proposal. Journal of Pathology, 2021, 254, 109-120.	4.5	5
15	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology, 2021, 23, 1231-1251.	1.2	4,534
16	EMBR-13. NOVEL SYNERGISTIC APPROACHES FOR TARGETED THERAPY OF MYC-DRIVEN MEDULLOBLASTOMA USING CRISPR/CAS9 GENE EDITING. Neuro-Oncology, 2021, 23, i8-i8.	1.2	0
17	Sarcomatous Meningioma: Diagnostic Pitfalls and the Utility of Molecular Testing. Journal of Neuropathology and Experimental Neurology, 2021, 80, 764-768.	1.7	4
18	The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma. Cell Death and Disease, 2021, 12, 885.	6.3	22

#	Article	IF	Citations
19	Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. Scientific Reports, 2021, 11, 17918.	3.3	22
20	Frequent Epigenetic Inactivation of DIRAS-1 and DIRAS-2 Contributes to Chemo-Resistance in Gliomas. Cancers, 2021, 13, 5113.	3.7	5
21	Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting. Archives of Pathology and Laboratory Medicine, 2020, 144, 196-206.	2.5	21
22	FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. Acta Neuropathologica, 2020, 139, 175-192.	7.7	15
23	Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 659-670.	2.5	14
24	4EBP1/2 are active under standard cell culture conditions to regulate the translation of specific mRNAs. Cell Death and Disease, 2020, 11, 968.	6.3	3
25	Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 782.	2.4	6
26	Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype. Nature Communications, 2020, 11, 6434.	12.8	48
27	Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?. Current Opinion in Neurology, 2020, 33, 701-706.	3.6	15
28	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathologica, 2020, 139, 603-608.	7.7	344
29	cIMPACTâ€NOW update 6: new entity and diagnostic principle recommendations of the cIMPACTâ€Utrecht meeting on future CNS tumor classification and grading. Brain Pathology, 2020, 30, 844-856.	4.1	363
30	MBRS-48. IDENTIFICATION OF NOVEL THERAPEUTIC APPROACHES FOR MYC-DRIVEN MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii406-iii406.	1.2	0
31	EPEN-33. PHARMACOGENOMICS REVEALS SYNERGISTIC INHIBITION OF ERBB2 AND PI3K SIGNALING AS A THERAPEUTIC STRATEGY FOR EPENDYMOMA. Neuro-Oncology, 2020, 22, iii314-iii314.	1.2	0
32	Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status. Neuro-Oncology Advances, 2020, 2, vdaa137.	0.7	2
33	MiRâ€16â€5p is frequently downâ€regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy. Neuropathology and Applied Neurobiology, 2019, 45, 441-458.	3.2	50
34	SIG-03. HHIP-AS1 PROMOTES TUMOR SURVIVAL THROUGH STABILIZING DYNEIN COMPLEX 1 IN HEDGEHOG DRIVEN HUMAN BRAIN TUMORS. Neuro-Oncology, 2019, 21, ii113-ii114.	1.2	1
35	Molecular targeted therapy of glioblastoma. Cancer Treatment Reviews, 2019, 80, 101896.	7.7	386
36	A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications. Cancer Research, 2019, 79, 1226-1238.	0.9	26

#	Article	IF	Citations
37	Pathology and Classification of Tumors of theÂCentral Nervous System. , 2019, , 3-89.		0
38	RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas. Acta Neuropathologica, 2019, 138, 275-293.	7.7	6
39	EPEN-08. PHARMACOGENOMICS REVEALS ERBB2 AS A THERAPEUTIC TARGET IN PRIMARY EPENDYMOMA CULTURES. Neuro-Oncology, 2019, 21, ii78-ii79.	1.2	0
40	Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. Cancer Cell, 2019, 35, 692-704.e12.	16.8	172
41	The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death and Disease, 2019, 10, 246.	6.3	129
42	Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup. American Journal of Surgical Pathology, 2018, 42, 506-511.	3.7	43
43	EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro-Oncology, 2018, 20, 445-456.	1.2	173
44	DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271.	7.7	59
45	USP8 Mutations in Pituitary Cushing Adenomasâ€"Targeted Analysis by Next-Generation Sequencing. Journal of the Endocrine Society, 2018, 2, 266-278.	0.2	40
46	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
47	A PRDX1â€p38Î± heterodimer amplifies METâ€driven invasion of IDHâ€wildtype and IDHâ€mutant gliomas. International Journal of Cancer, 2018, 143, 1176-1187.	5.1	14
48	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	7.7	190
49	Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma in vitro. Oncotarget, 2018, 9, 22703-22716.	1.8	50
50	MBRS-16. HDAC AND NFÎºB ANTAGONISTS SYNERGISTICALLY INHIBIT GROWTH OF MYC-DRIVEN MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i131-i131.	1.2	0
51	cIMPACT-NOW update 3: recommended diagnostic criteria for â€œDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IVâ€. Acta Neuropathologica, 2018, 136, 805-810.	7.7	599
52	ATRT-34. TARGETING PRIMARY CILIOGENESIS IN ATYPICAL TERATOID/RHABDOID TUMORS. Neuro-Oncology, 2018, 20, i35-i35.	1.2	0
53	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathologica, 2018, 136, 793-803.	7.7	195
54	Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. Cancer Cell, 2018, 34, 379-395.e7.	16.8	104

#	Article	IF	Citations
55	D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells. Clinical Cancer Research, 2018, 24, 5381-5391.	7.0	55
56	Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Gliomaâ€Tailored Gene Panel. Brain Pathology, 2017, 27, 146-159.	4.1	130
57	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncology, The, 2017, 18, e315-e329.	10.7	816
58	Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathologica Communications, 2017, 5, 39.	5.2	110
59	Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma. Neurology, 2017, 88, 1422-1430.	1.1	54
60	Advances in the molecular genetics of gliomas â€" implications for classification and therapy. Nature Reviews Clinical Oncology, 2017, 14, 434-452.	27.6	497
61	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	7.7	120
62	Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis. Acta Neuropathologica, 2017, 134, 905-922.	7.7	12
63	Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. Clinical Cancer Research, 2017, 23, 6846-6855.	7.0	151
64	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 2016, 18, now133.	1.2	130
65	Role of micro<scp>RNA</scp>s Located on Chromosome Arm 10q in Malignant Gliomas. Brain Pathology, 2016, 26, 344-358.	4.1	26
66	Molecular classification of gliomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 97-120.	1.8	90
67	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 2016, 131, 803-820.	7.7	12,144
68	Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. Current Opinion in Oncology, 2016, 28, 494-501.	2.4	62
69	Limited role for transforming growth factorâ€"Î² pathway activation-mediated escape from VEGF inhibition in murine glioma models. Neuro-Oncology, 2016, 18, 1610-1621.	1.2	27
70	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastomaâ€"results from the DIRECTOR trial. Neuro-Oncology, 2016, 18, 549-556.	1.2	187
71	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
72	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget, 2016, 7, 82028-82045.	1.8	21

#	Article	IF	Citations
73	Glioma. Nature Reviews Disease Primers, 2015, 1, 15017.	30.5	718
74	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	7.7	277
75	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	7.7	237
76	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathologica, 2015, 129, 679-693.	7.7	254
77	Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathologica, 2015, 129, 829-848.	7.7	503
78	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. Neuro-Oncology, 2014, 16, 1630-1638.	1.2	77
79	Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. International Journal of Cancer, 2014, 134, 2437-2447.	5.1	100
80	MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation. Neuro-Oncology, 2014, 16, 179-190.	1.2	78
81	Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wildâ€type glioblastoma. Genes Chromosomes and Cancer, 2014, 53, 589-605.	2.8	18
82	Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. International Journal of Cancer, 2014, 135, 1822-1831.	5.1	117
83	EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncology, The, 2014, 15, e395-e403.	10.7	647
84	Interferon-Î² Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells. Molecular Cancer Therapeutics, 2014, 13, 948-961.	4.1	47
85	<scp>I</scp>nternational <scp>S</scp>ociety of <scp>N</scp>europathologyâ€<scp>H</scp>aarlem <scp>C</scp>onsensus <scp>G</scp>uidelines for <scp>N</scp>ervous <scp>S</scp>ystem <scp>T</scp>umor <scp>C</scp>lassification and <scp>G</scp>rading. Brain Pathology, 2014, 24, 429-435.	4.1	499
86	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathologica, 2014, 128, 561-571.	7.7	176
87	MGMT testingâ€”the challenges for biomarker-based glioma treatment. Nature Reviews Neurology, 2014, 10, 372-385.	10.1	454
88	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	21.4	674
89	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathologica, 2013, 125, 913-916.	7.7	244
90	EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma. Cancer Cell, 2013, 24, 438-449.	16.8	219

#	Article	IF	Citations
91	Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 2013, 81, 1515-1522.	1.1	211
92	Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations. Clinical Cancer Research, 2013, 19, 5146-5157.	7.0	157
93	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathologica, 2012, 124, 615-625.	7.7	376
94	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, The, 2012, 13, 707-715.	10.7	980
95	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 2012, 22, 425-437.	16.8	1,551
96	Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. Journal of Neurochemistry, 2012, 122, 444-455.	3.9	120
97	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482, 226-231.	27.8	2,129
98	Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. International Journal of Cancer, 2012, 131, 1342-1350.	5.1	220
99	DNA Hypermethylation and Histone Modifications Downregulate the Candidate Tumor Suppressor Gene RRP22 on 22q12 in Human Gliomas. Brain Pathology, 2012, 22, 17-25.	4.1	21
100	Unraveling the Glioma Epigenomeâ€"From Molecular Mechanisms to Novel Biomarkers and Therapeutic Targets. Brain Pathology, 2011, 21, 619-632.	4.1	38
101	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathologica, 2011, 121, 397-405.	7.7	914
102	SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathologica, 2011, 122, 241-251.	7.7	70
103	Molecular signatures classify astrocytic gliomas by IDH1 mutation status. International Journal of Cancer, 2011, 128, 1095-1103.	5.1	75
104	Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. International Journal of Cancer, 2011, 129, 659-670.	5.1	247
105	Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?. Clinical Cancer Research, 2011, 17, 4588-4599.	7.0	179
106	Differential Retinoic Acid Signaling in Tumors of Long- and Short-term Glioblastoma Survivors. Journal of the National Cancer Institute, 2011, 103, 598-601.	6.3	46
107	MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nature Reviews Neurology, 2010, 6, 39-51.	10.1	644
108	Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathologica, 2010, 119, 501-507.	7.7	108

#	Article	IF	Citations
109	Molecular diagnostics of gliomas: state of the art. Acta Neuropathologica, 2010, 120, 567-584.	7.7	243
110	Molecular diagnostics of brain tumors. Acta Neuropathologica, 2010, 120, 549-551.	7.7	4
111	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica, 2010, 120, 707-718.	7.7	719
112	MGMT promoter methylation in malignant gliomas. Targeted Oncology, 2010, 5, 161-165.	3.6	66
113	Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. Journal of Neuro-Oncology, 2010, 97, 389-392.	2.9	72
114	Identification and Functional Characterization of microRNAs Involved in the Malignant Progression of Gliomas. Brain Pathology, 2010, 20, 539-550.	4.1	324
115	Hypermethylation and Transcriptional Downregulation of the TIMP3 Gene is Associated with Allelic Loss on 22q12.3 and Malignancy in Meningiomas. Brain Pathology, 2010, 20, 623-631.	4.1	74
116	Epigenetic Downregulation of Mitogen-Activated Protein Kinase Phosphatase MKP-2 Relieves Its Growth Suppressive Activity in Glioma Cells. Cancer Research, 2010, 70, 1689-1699.	0.9	66
117	Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. Neuro-Oncology, 2010, 12, 243-256.	1.2	32
118	Pathology and Classification of Tumors of the Nervous System. , 2010, , 3-75.		8
119	Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients. Clinical Cancer Research, 2009, 15, 6683-6693.	7.0	180
120	Molecular Neuropathology of Gliomas. International Journal of Molecular Sciences, 2009, 10, 184-212.	4.1	42
121	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica, 2009, 118, 469-474.	7.7	1,020
122	Simultaneous extraction of nucleic acids and proteins from tissue specimens by ultracentrifugation: A protocol using the highâ€salt protein fraction for quantitative proteome analysis. Proteomics, 2009, 9, 4985-4990.	2.2	11
123	NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology, 2009, 27, 5874-5880.	1.6	743
124	Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide. Journal of Clinical Oncology, 2009, 27, 1257-1261.	1.6	128
125	Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network. Journal of Clinical Oncology, 2009, 27, 5743-5750.	1.6	534
126	Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. Current Opinion in Neurology, 2009, 22, 619-624.	3.6	8

#	Article	IF	Citations
127	Astrocytic Tumors. Recent Results in Cancer Research, 2009, 171, 3-24.	1.8	21
128	Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss. International Journal of Cancer, 2008, 122, 2503-2510.	5.1	36
129	Haplotypeâ€specific expression of the human PDGFRA gene correlates with the risk of glioblastomas. International Journal of Cancer, 2008, 123, 322-329.	5.1	18
130	Antiâ€Ó6â€Methylguanineâ€Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*. Brain Pathology, 2008, 18, 520-532.	4.1	189
131	Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma. Cancer Research, 2008, 68, 5706-5715.	0.9	269
132	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. Journal of Clinical Investigation, 2008, 118, 1739-1749.	8.2	437
133	Long-term survival with glioblastoma multiforme. Brain, 2007, 130, 2596-2606.	7.6	748
134	Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma. Journal of Clinical Oncology, 2007, 25, 3357-3361.	1.6	237
135	Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors. International Journal of Cancer, 2007, 120, 2368-2376.	5.1	35
136	Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. International Journal of Cancer, 2007, 121, 2458-2464.	5.1	140
137	DNA hypermethylation and Aberrant Expression of the EMP3 Gene at 19q13.3 in Human Gliomas. Brain Pathology, 2007, 17, 363-370.	4.1	47
138	Loss of NOTCH2 Positively Predicts Survival in Subgroups of Human Glial Brain Tumors. PLoS ONE, 2007, 2, e576.	2.5	60
139	Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03. Journal of Clinical Oncology, 2006, 24, 4412-4417.	1.6	152
140	Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. International Journal of Cancer, 2006, 119, 792-800.	5.1	66
141	Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction. International Journal of Cancer, 2006, 119, 2330-2338.	5.1	58
142	Pathology and Classification of Tumors of the Nervous System. , 2006, , 3-72.		3
143	Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathology and Applied Neurobiology, 2005, 31, 486-490.	3.2	79
144	Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. International Journal of Cancer, 2005, 113, 379-385.	5.1	246

#	Article	IF	Citations
145	Molecular classification of human gliomas using matrix-based comparative genomic hybridization. International Journal of Cancer, 2005, 117, 95-103.	5.1	36
146	Hypermethylation and Transcriptional Downregulation of the Carboxyl-Terminal Modulator Protein Gene in Glioblastomas. Journal of the National Cancer Institute, 2004, 96, 483-486.	6.3	57
147	Oligodendroglial Tumors: Refinement of Candidate Regions on Chromosome Arm 1p and Correlation of 1p/19q Status with Survival. Brain Pathology, 2004, 14, 121-130.	4.1	148
148	Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas. Acta Neuropathologica, 2004, 107, 277-282.	7.7	59
149	Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathologica, 2004, 108, 467-470.	7.7	136
150	Pathology and molecular genetics of astrocytic gliomas. Journal of Molecular Medicine, 2004, 82, 656-670.	3.9	147
151	Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. International Journal of Cancer, 2004, 109, 377-384.	5.1	133
152	Absence of mutations in the putative tumor suppressor geneKLF6in glioblastomas and meningiomas. International Journal of Cancer, 2004, 111, 644-645.	5.1	21
153	Absence of detectable alterations in the putative tumor suppressor gene BTRC in cerebellar medulloblastomas and cutaneous basal cell carcinomas. Acta Neuropathologica, 2003, 106, 287-290.	7.7	13
154	Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. International Journal of Cancer, 2003, 104, 752-757.	5.1	85
155	Characterization of Gene Expression Profiles Associated with Glioma Progression Using Oligonucleotide-Based Microarray Analysis and Real-Time Reverse Transcription-Polymerase Chain Reaction. American Journal of Pathology, 2003, 163, 1033-1043.	3.8	284
156	Oligodendroglioma: Toward Molecular Definitions in Diagnostic Neuro-Oncology. Journal of Neuropathology and Experimental Neurology, 2003, 62, 111-126.	1.7	280
157	Genetic Alterations and Aberrant Expression of Genes Related to the Phosphatidylâ€Inositolâ€3â€²â€Kinase/Protein Kinase B (Akt) Signal Transduction Pathway in Glioblastomas. Brain Pathology, 2003, 13, 507-518.	4.1	200
158	Genetic Alterations Commonly Found in Diffusely Infiltrating Cerebral Gliomas Are Rare or Absent in Pleomorphic Xanthoastrocytomas. Journal of Neuropathology and Experimental Neurology, 2002, 61, 1092-1099.	1.7	53
159	Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genesCTNNB1, APC, ICAT andBTRC. International Journal of Cancer, 2002, 100, 549-556.	5.1	117
160	Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes and Cancer, 2002, 34, 416-427.	2.8	122
161	Pten signaling in gliomas. Neuro-Oncology, 2002, 4, 196-211.	1.2	73
162	Analysis of human meningiomas for aberrations of theMADH2,MADH4,APM-1 andDCC tumor suppressor genes on the long arm of chromosome 18. International Journal of Cancer, 2001, 92, 551-554.	5.1	28

#	Article	IF	Citations
163	Somatic mutations ofWNT/wingless signaling pathway components in primitive neuroectodermal tumors. International Journal of Cancer, 2001, 93, 445-449.	5.1	161
164	Oligodendroglial Tumors Frequently Demonstrate Hypermethylation of theCDKN2A(MTS1,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf andCDKN2B(MTS2,p15^{INK4b}) Tumor Suppressor Genes. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1170-1180.	1.7	81
165	Molecular Genetic Analysis of Ependymal Tumors. American Journal of Pathology, 1999, 155, 627-632.	3.8	226
166	Identification of Two Distinct Deleted Regions on the Short Arm of Chromosome 1 and Rare Mutation of theCDKN2CGene from 1p32 in Oligodendroglial Tumors. Journal of Neuropathology and Experimental Neurology, 1999, 58, 1041-1050.	1.7	77
167	Frequent In activation of CDKN2A and Rare Mutation of TP53 in PCNSL. Brain Pathology, 1998, 8, 263-276.	4.1	65
168	Analysis of p53 Mutation and Epidermal Growth Factor Receptor Amplification in Recurrent Gliomas with Malignant Progression. Journal of Neuropathology and Experimental Neurology, 1996, 55, 822-831.	1.7	142
169	MUTATION OF THE VON HIPPEL-LINDAU TUMOUR SUPPRESSOR GENE IN CAPILLARY HAEMANGIOBLASTOMAS OF THE CENTRAL NERVOUS SYSTEM. , 1996, 179, 151-156.		65